Latest News

Novozymes bags Organobalance

Enzyme fermentation at Novozymes' pilot plant, in Bagsværd, Denmark © Novozymes


Denmark’s Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology.

Germany-based Organobalance specializes in developing natural microbial solutions for customers and partners across a number of industries including food, feed, and animal health. Now, the company with a staff of 29  has been bought up by Danish industrial enzymes and microorganism expert Novozymes for an undisclosed amount.

“The experience of Organobalance’s founding scientists, and the company’s know-how, immediately strengthen Novozymes’ existing capabilities within microbial technologies,” says Sebastian Søderberg, Vice President for New Business Development, Incubation & Acquisitions at Novozymes. “Organobalance will advance our understanding to develop new, sustainable solutions across industries, and provide us with additional commercial opportunities.”

Organobalance co-founder Christine Lang will continue as General Manager. Lang commented: “By becoming part of Novozymes, we will have access to a global R&D network and an extensive infrastructure to bring products to market – a clear advantage for us and our customers."

Nanosyrinx raises £6.2m to validate drug delivery platform

The financing round was co-led by incoming Octopus Ventures and existing Dutch investor M Ventures (Amsterdam), the corporate venture capital arm of...

Call for pull incentives to get started

With around 30 international experts in the line-up, the virtual conference discussed the current state of the fight against antimicrobial resistance...

Bayer takes over Vividion

The acquisition strengthens Bayer's oncology and immunology pipeline and secures a revolutionary screening technology for small molecule drugs that...

Data protection rules may block medical progress

On Monday, EU data protection agencies asked for a “general ban” on the  “recognition of faces, gait, fingerprints, DNA, voice, keystrokes and...

US$21m for microbiome therapies

Scottish biopharmaceutical company EnteroBiotix is focussed on addressing a wide range of diseases by enhancing the diversity of the microbiome. Now,...

Coriolis Pharma expands its ATMP development facilities

The cell and gene therapy formulation R&D specialist will add a BSL2 facility, totaling Coriolis Pharma’s floor space to 7,800 m2. The new...

VectivBio expands rare disease pipeline

Under the terms of the agreement, VectivBio will acquire Comet Therapeutics in exchange for equity and cash payable at closing, as well as additional...